Zinc-Gripping Toxins: New Therapies Take Aim at Snake Venom Metalloproteinases

Snakebite envenoming remains one of the most neglected crises in global health, and a new review published in Molecular Biology Reports argues that the key to better treatment may lie in a single family of venom enzymes. The work, led by Jagadeesh Dodakallanavar and colleagues at the ICMR National Institute of Traditional Medicine in Belagavi, India, together with collaborators at KLE College of Pharmacy, synthesizes decades of research on snake venom metalloproteinases, or SVMPs, the zinc-dependent enzymes that drive much of the tissue destruction, hemorrhage and swelling seen after viper bites. By mapping the structural architecture of these toxins and surveying the expanding arsenal of inhibitors directed against them, the authors lay out a roadmap for next-generation therapies that could complement, and perhaps eventually replace, conventional antivenom.

SVMPs belong to the metzincin superfamily of metalloproteases, a group that also includes the mammalian matrix metalloproteinases and the ADAM and ADAMTS proteins. What unites them is a conserved catalytic motif, HEXXHXXGXXH, which coordinates a single zinc ion essential for cleaving peptide bonds. When a viper strikes, these enzymes flood the victim’s tissues and begin systematically dismantling the extracellular matrix and basement membranes that hold blood vessels together. The result is the characteristic pathology of hemotoxic envenoming: capillary leakage, profuse local and systemic bleeding, edema, blistering and progressive necrosis. Because the enzymes are so efficient at degrading structural proteins such as collagen, laminin and perlecan, even relatively small amounts can destabilize the microvasculature within minutes of a bite.

The review emphasizes that SVMPs are not a single entity but a structurally diverse family classified into three principal classes based on their domain organization. P-I enzymes consist of a catalytic metalloproteinase domain alone, making them the simplest members of the family. P-II toxins add a disintegrin-like domain, which allows them to interfere with platelet aggregation by binding integrin receptors, while P-III enzymes carry additional domains, including cysteine-rich and C-type lectin-like regions, that expand their repertoire of interactions with host tissues. This modular architecture explains why SVMPs produce such a bewildering range of effects, from direct hemorrhage to inflammation, apoptosis of vascular cells and disruption of blood coagulation. It also means that a therapeutic strategy effective against one class may fail against another, a central challenge for anyone attempting broad-spectrum neutralization.

The molecular pathogenesis of SVMP-mediated damage has been worked out over more than half a century, beginning with early enzymatic studies of habu snake venom in the late 1950s and the landmark isolation of hemorrhagic toxins from western diamondback rattlesnake venom in the 1970s, which first established the critical role of zinc. Subsequent electron microscopy and biochemical work showed that these enzymes attack the basement membrane of capillaries, weakening the vessel wall until the sheer pressure of blood flow causes it to rupture. More recent studies have revealed additional layers of pathology: SVMPs such as jararhagin from Bothrops jararaca trigger the release of pro-inflammatory cytokines, recruit immune cells that contribute to necrosis, and induce apoptosis of endothelial cells through vascular apoptosis-inducing proteins identified in rattlesnake venom. Some members of the family also perturb the coagulation cascade, either degrading clotting factors or activating them inappropriately, compounding the bleeding disorder.

Against this backdrop, the limitations of conventional antivenom therapy loom large. Antivenoms, produced by immunizing horses or sheep with venom and purifying the resulting antibodies, remain the only approved treatment worldwide, and the World Health Organization classifies them as essential medicines. Yet they are expensive, require cold-chain distribution and hospital administration, and are most effective against systemic effects such as coagulopathy. Local tissue damage, which begins almost immediately after the bite, is often already irreversible by the time antivenom is infused. Antibody molecules also distribute poorly into peripheral tissues, leaving the very compartments where SVMPs inflict their worst damage relatively unprotected. These shortcomings have pushed researchers toward small molecules and engineered biologics that can be administered early, potentially even in the field.

The review surveys several promising classes of SVMP inhibitors. Plant-derived compounds have attracted particular attention, especially from research groups in regions where snakebite burden is highest. Flavonoids such as myricetin have been shown to inhibit venom metalloproteinases, while rosmarinic acid from Argusia argentea suppresses hemorrhage induced by habu venom, and gallic acid reduces the toxic activities of Bothrops jararaca and Bothrops jararacussu venoms. Lapachol analogs from plants have emerged as selective metalloprotease inhibitors active against Bothrops venom, and mango seed kernel extracts have demonstrated anti-SVMP activity supported by molecular docking studies. Ethnopharmacological approaches, including a recent combined computational and experimental evaluation of Plumbago zeylanica against Russell’s viper envenomation by members of the same Indian team, continue to feed candidate compounds into the pipeline, although the review notes that herbal remedies face significant hurdles on the path to clinical validation.

Synthetic and repurposed small molecules represent perhaps the most clinically advanced frontier. Zinc-chelating agents can strip the catalytic metal from SVMPs and have shown protection against the proteolytic, hemorrhagic and myotoxic activities of saw-scaled viper venom. The most striking example is varespladib, a drug originally developed for cardiovascular indications, which has been preclinically validated as an early-intervention treatment for hemotoxic snakebite and shown to protect against venom lethality in combination with broadly neutralizing human antibodies. Matrix metalloproteinase inhibitors designed for oncology, such as marimastat and prinomastat, display differential activity against the metalloprotease components of various snake venoms, and recent medicinal chemistry efforts have identified DC-174, a hydroxamic acid pre-candidate being developed as an oral snakebite treatment. High-throughput screening campaigns dedicated specifically to SVMP inhibitors are now systematically expanding this chemical space.

Biologics are advancing in parallel. Monoclonal antibodies raised against specific SVMPs, including mutalysin-II, atroxlysin-I and the hemorrhagic toxin HR1a from Protobothrops flavoviridis, have neutralized hemorrhagic activity in experimental settings, and phylogenetically conserved epitopes shared across SVMPs offer hope for antibodies with broad cross-species coverage. Even more striking are camelid-derived nanobodies, the tiny single-domain antibody fragments prized for their stability, tissue penetration and ease of bacterial production. A landmark study published in Nature in 2025 demonstrated a nanobody-based recombinant antivenom effective against cobra, mamba and rinkhals bites, and nanobodies targeting hemorrhagic and myotoxic components of Bothrops atrox venom have been developed independently. These recombinant platforms promise antivenoms that are more consistent, cheaper to manufacture and rationally designed against defined toxins rather than whole venom cocktails.

The review closes by highlighting technologies that could accelerate discovery across all these fronts. Snake venom gland organoids, first derived in 2020, allow researchers to culture venom-producing tissue in vitro, providing a renewable source of toxins for functional testing and a platform for CRISPR-based target validation. Artificial intelligence and machine learning are being deployed to mine venom proteomes, predict inhibitor binding and prioritize candidates for synthesis, while structure-based drug discovery and molecular docking continue to illuminate how inhibitors engage the catalytic zinc and surrounding substrate-recognition pockets. The authors argue that integrating these computational, biotechnological and pharmacological approaches offers a realistic path toward precise, broad-spectrum and affordable interventions against SVMP-mediated envenoming, a goal that could transform outcomes for the millions of people, most of them rural and impoverished, who suffer snakebites each year.

Subject of Research: Structure, pathogenic mechanisms and therapeutic inhibition of snake venom metalloproteinases

Article Title: Targeting snake venom metalloproteinases: structural diversity, molecular pathogenesis and therapeutic interventions

Article References: Dodakallanavar, J., Harish, D. R., Hiremath, K., Sampat, G. H., Patil, V. S., Mahadevamurthy, R. K., Ugare, S., Akula, K. K., & Manjunathachar, H. V. (2026). Targeting snake venom metalloproteinases: structural diversity, molecular pathogenesis and therapeutic interventions. Molecular Biology Reports, 53(1), Article 1619. https://doi.org/10.1007/s11033-026-12781-z

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12781-z

Keywords: snake venom metalloproteinases, SVMPs, snakebite envenoming, antivenom, zinc-dependent proteases, metzincins, small molecule inhibitors, nanobodies, recombinant antibodies, varespladib, venom gland organoids, structure-based drug discovery